Roche: FDA approves faster breast cancer drug formulation

(CercleFinance.com) - Roche said that the FDA has approved a combination of breast cancer drugs Perjeta and Herceptin which offers administration in just minutes, compared to hours with standard administration.


The Food and Drug Administration has approved Phesgo, in combination with chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer, the Swiss drugmaker said late on Monday.

This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single injection.

Phesgo's under-the-skin administration takes approximately eight minutes, compared to approximately 150 minutes for a sequential infusion of Perjeta and Herceptin using intravenous formulations.

Copyright (c) 2020 CercleFinance.com. All rights reserved.